Ontology highlight
ABSTRACT:
SUBMITTER: Kusnadi EP
PROVIDER: S-EPMC7604608 | biostudies-literature | 2020 Nov
REPOSITORIES: biostudies-literature
Kusnadi Eric P EP Trigos Anna S AS Cullinane Carleen C Goode David L DL Larsson Ola O Devlin Jennifer R JR Chan Keefe T KT De Souza David P DP McConville Malcolm J MJ McArthur Grant A GA Thomas George G Sanij Elaine E Poortinga Gretchen G Hannan Ross D RD Hannan Katherine M KM Kang Jian J Pearson Richard B RB
The EMBO journal 20200918 21
Elevated ribosome biogenesis in oncogene-driven cancers is commonly targeted by DNA-damaging cytotoxic drugs. Our previous first-in-human trial of CX-5461, a novel, less genotoxic agent that specifically inhibits ribosome biogenesis via suppression of RNA polymerase I (Pol I) transcription, revealed single-agent efficacy in refractory blood cancers. Despite this clinical response, patients were not cured. In parallel, we demonstrated a marked improvement in the in vivo efficacy of CX-5461 in com ...[more]